Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SOHO 2022 and Soho 2022 View overview page

4:22
Current challenges in CAR-T cell therapy and the role of the tumor microenvironment
Saad Kenderian • 5 Oct 2022
5:22
Determining the optimal dose of induction therapy for patients with AML
Selina Luger • 6 Oct 2022
1:09
Using MRD and mutational analysis when selecting patients with T-ALL for transplantation
Josep-Maria Ribera • 3 Oct 2022
1:00
The adverse prognostic impact of complex karyotype in adult T-ALL
Josep-Maria Ribera • 3 Oct 2022
5:16
Approaches to and the use of MRD in ALL
Selina Luger • 6 Oct 2022
3:49
The challenges in developing bispecific antibodies for non-Hodgkin lymphoma
Michael Dickinson • 30 Sep 2022
1:40
Major unmet needs in the MCL patient population
Jonathon Cohen • 7 Oct 2022
3:26
Implications of RAS mutational status in subsets of patients with newly diagnosed AML
Tapan Kadia • 29 Sep 2022
1:33
Updates from the IKEMA trial: Isa-Kd versus Kd in R/R multiple myeloma
Thomas Martin • 30 Sep 2022
3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
2:42
Promising cellular therapies emerging in multiple myeloma
Peter Voorhees • 30 Sep 2022
1:36
Novel therapeutic regimens being explored in PTCL
Neha Mehta-Shah • 30 Sep 2022
1:24
The current understanding and approach to breast implant-associated anaplastic large cell lymphoma
Neha Mehta-Shah • 30 Sep 2022
4:15
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Peter Voorhees • 30 Sep 2022
2:39
The role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents
Peter Voorhees • 30 Sep 2022
5:05
Determining the most suitable consolidation therapies for AML by defining patient risk group
Selina Luger • 6 Oct 2022
The content of VJHemOnc is intended for healthcare professionals